Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000253478 | SCV000303077 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Illumina Laboratory Services, |
RCV000388135 | SCV000353601 | benign | Junctional epidermolysis bullosa | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000589851 | SCV000696000 | benign | not provided | 2016-12-05 | criteria provided, single submitter | clinical testing | Variant summary: The LAMB3 c.2702-12dupG variant involves the alteration of a non-conserved intronic nucleotide. Mutation Taster predicts a benign outcome for this variant. In addition, 4/5 splice prediction tools predict no significant impact on normal splicing. This variant was found in 114615/119804 control chromosomes (including 54857 homozygotes) at a frequency of 0.9566876, which is approximately 1027 times the estimated maximal expected allele frequency of a pathogenic LAMB3 variant (0.0009317), thus this variant is a benign polymorphism and allele dupG is the major allele at this cDNA position. In addition, a clinical diagnostic laboratory has also classified this variant as benign. Taken together, this variant is classified as Benign. |
Gene |
RCV000589851 | SCV001913303 | benign | not provided | 2015-03-03 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001730607 | SCV001981272 | benign | Junctional epidermolysis bullosa gravis of Herlitz | 2021-08-19 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001730608 | SCV001981273 | benign | Junctional epidermolysis bullosa, non-Herlitz type | 2021-08-19 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000589851 | SCV002454423 | benign | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing |